生物电阻抗分析诊断肌少症:系统综述与荟萃分析
该系统综述与荟萃分析纳入27项研究共6239名参与者,评估生物电阻抗分析(BIA)检测肌少症的诊断性能。汇总敏感度为79%(95%CI 75%-82%),特异度为72%(95%CI 68%-75%),SROC-AUC为0.82(95%CI 0.78-0.85),提示BIA具有中等诊断准确性,可作为肌少症筛查工具,尤其适用于初级保健和社区场景。
要点
- BIA检测肌少症的汇总敏感度为79%,特异度为72%。
- 汇总SROC-AUC为0.82,提示中等诊断准确性。
- BIA可作为肌少症筛查工具,尤其适用于初级保健和社区场景。
核心结论
- BIA作为肌少症筛查工具具有中等诊断准确性和实用临床价值,尤其适用于初级保健和社区场景。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Embase和Web of Science截至2024年1月2日,纳入横断面、回顾性和前瞻性队列研究,共27项研究6239名参与者。
主要发现
- 汇总敏感度为79%(95%CI 75%-82%),汇总特异度为72%(95%CI 68%-75%)。
- 汇总阳性似然比为2.8(95%CI 2.5-3.1),汇总阴性似然比为0.29(95%CI 0.25-0.35)。
- 汇总诊断比值比为9(95%CI 7-12),SROC-AUC为0.82(95%CI 0.78-0.85)。
- 敏感性分析证实结果稳健,但存在异质性,归因于临床和方法学因素变异。
关键数值与推荐
- BIA诊断肌少症的汇总敏感度79%(95%CI 75%-82%),特异度72%(95%CI 68%-75%),PLR 2.8(95%CI 2.5-3.1),NLR 0.29(95%CI 0.25-0.35),DOR 9(95%CI 7-12),SROC-AUC 0.82(95%CI 0.78-0.85)。
临床怎么用
- BIA可作为肌少症筛查工具用于初级保健和社区场景,但需注意其诊断准确性为中等,并需进一步研究标准化方案和预测模型。
局限性
- 存在异质性,归因于临床和方法学因素变异;需进一步研究制定标准化方案和预测模型以提高一致性和可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the diagnostic performance of bioelectrical impedance analysis (BIA) for detecting sarcopenia across diverse populations. METHODS: We conducted a search of MEDLINE, Embase, and Web of Science up to 2 January 2024. Cross-sectional, retrospective, and prospective cohort studies evaluating BIA's diagnostic performance for detecting sarcopenia across diverse populations were included. The pooled sensitivity, specificity, positive and negative likelihood ratios (positive likelihood ratio [PLR] and negative likelihood ratio [NLR]), diagnostic odds ratio (DOR), and the area under the curve of summary receiver operating characteristic (SROC-AUC) were calculated using bivariate random-effects models. For each outcome, 95% confidence intervals (CI) were reported. RESULTS: A total of 27 studies involving 6239 participants were included. The pooled sensitivity was 79% (95% CI, 75%-82%), and the pooled specificity was 72% (95% CI, 68%-75%). The pooled PLR was 2.8 (95% CI, 2.5-3.1), the pooled NLR was 0.29 (95% CI, 0.25-0.35), and the pooled DOR was 9 (95% CI, 7-12). The SROC-AUC was 0.82 (95% CI, 0.78-0.85). Sensitivity analysis confirmed the robustness of these results. Heterogeneity was observed, which was attributable to variations in clinical and methodological factors. CONCLUSIONS: This systematic review indicates that BIA has moderate diagnostic accuracy and practical clinical utility as a screening tool for sarcopenia, particularly in primary care and community settings. Further research is warranted to develop standardised protocols and predictive models to enhance consistency and reliability across populations.
引用
- Luo M, Duan Z, Li Y, et al. Bioelectrical impedance analysis for sarcopenia: a systematic review and meta-analysis of diagnostic accuracy. Age Ageing. 2025. PMID: 40586124. doi:10.1093/ageing/afaf181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。